Assignee
AOP ORPHAN PHARMACEUTICALS AG
AT·7 granted patents·9 pending applications·0 citations·filing 2008–2022
Top patents by PatentIndex Score
16 records- 0176US2023277674A1Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonistsAOP ORPHAN PHARMACEUTICALS AG·Filed 2022·Application pending·0 cites
- 0271US11963940B2Parenteral esmolol formulationAOP ORPHAN PHARMACEUTICALS AG·Filed 2022·Granted Apr 23, 2024·0 cites·10 claims
- 0369US10660964B2Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonistsAOP ORPHAN PHARMACEUTICALS AG·Filed 2018·Granted May 26, 2020·0 cites·8 claims
- 0468US11517624B2Pharmaceutical composition for the parenteral administration of ultrashort-effective β-adrenoreceptor antagonistsAOP ORPHAN PHARMACEUTICALS AG·Filed 2020·Granted Dec 6, 2022·0 cites·12 claims
- 0561US2010311738A1Pharmaceutical Composition For The Parenteral Administration Of Ultrashort-Effective Beta-Adrenoreceptor AntagonistsAOP ORPHAN PHARMACEUTICALS AG·Filed 2008·Application pending·0 cites
- 0652US2016361422A1Pharmaceutical Composition for the Parenteral Administration of Ultrashort-Effective Beta-Adrenoreceptor AntagonistsAOP ORPHAN PHARMACEUTICALS AG·Filed 2016·Application pending·0 cites
- 0750US2015087704A1Parenteral esmolol formulationAOP ORPHAN PHARMACEUTICALS AG·Filed 2013·Application pending·0 cites
- 0850US2015086637A1Novel composition for treatment of essential thrombocythemiaAOP ORPHAN PHARMACEUTICALS AG·Filed 2014·Application pending·0 cites
- 0948US9782413B2Composition for treatment of essential thrombocythemiaAOP ORPHAN PHARMACEUTICALS AG·Filed 2016·Granted Oct 10, 2017·0 cites·9 claims
- 1048US2017326095A1Parenteral esmolol formulationAOP ORPHAN PHARMACEUTICALS AG·Filed 2017·Application pending·0 cites
- 1147US10940136B2Cannabinoids for prophylactic treatment of involuntary weight lossAOP ORPHAN PHARMACEUTICALS AG·Filed 2017·Granted Mar 9, 2021·0 cites·18 claims
- 1246US2018028538A1Novel composition for treatment of essential thrombocythemiaAOP ORPHAN PHARMACEUTICALS AG·Filed 2017·Application pending·0 cites
- 1344US10722516B2Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmiasAOP ORPHAN PHARMACEUTICALS AG·Filed 2014·Granted Jul 28, 2020·0 cites·15 claims
- 1444US2021212985A1Cannabinoids for prophylactic treatment of involuntary weight lossAOP ORPHAN PHARMACEUTICALS AG·Filed 2021·Application pending·0 cites
- 1542US10329254B2Process for the preparation of 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide and intermediates thereofAOP ORPHAN PHARMACEUTICALS AG·Filed 2016·Granted Jun 25, 2019·0 cites·18 claims
- 1642US2013028945A1Novel composition for treatment of essential thrombocythemiaAOP ORPHAN PHARMACEUTICALS AG·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when AOP ORPHAN PHARMACEUTICALS AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →